NEXTBIOMEDICAL Co., Ltd. Logo

NEXTBIOMEDICAL Co., Ltd.

Develops polymer-based drug-device solutions for hemostasis and drug delivery worldwide.

389650 | KO

Overview

Corporate Details

ISIN(s):
KR7389650003
LEI:
Country:
South Korea
Address:
인천광역시 연수구 벤처로100번길 6, 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NEXTBIOMEDICAL Co., Ltd. is a global company specializing in innovative therapeutic solutions designed to address unmet clinical needs. The company develops and commercializes first-in-class products based on its proprietary polymer core technology, which enables advanced drug-device combination platforms. Key technologies include biodegradable adhesive polymers and resorbable microspheres for applications like sustained drug delivery. A flagship product is Nexpowder, an endoscopic hemostatic agent for gastrointestinal bleeding. Through strategic global partnerships, including a collaboration with Medtronic, NEXTBIOMEDICAL aims to establish its innovations as new standards of care worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-11 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-09-05 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 947.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 792.4 KB
2025-03-31 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 98.2 KB
2025-03-24 00:00
AGM Information
정기주주총회결과
Korean 20.3 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 22.7 KB
2025-03-13 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.1 MB
2025-03-11 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 88.0 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 84.7 KB
2025-02-20 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 23.4 KB
2025-02-12 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.2 KB
2025-02-12 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.9 KB
2025-02-04 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.0 KB
2024-12-24 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB

Automate Your Workflow. Get a real-time feed of all NEXTBIOMEDICAL Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NEXTBIOMEDICAL Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NEXTBIOMEDICAL Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM

Talk to a Data Expert

Have a question? We'll get back to you promptly.